-
Russia pummels Kyiv, killing three and denting peace hopes
-
Subdued Trump left waiting for 'big hug' from Xi
-
Slot has 'every reason to believe' he will remain as Liverpool boss
-
British PM battles to stay in power amid rebellion
-
Ex-Philippine drug war enforcer flees Senate refuge
-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
-
Indian pharma fuels Africa's 'zombie drug' and opioid crisis
-
After months of blackout, Iran gives internet to select few
-
Wood urges New Zealand to 'create some history' at World Cup
-
In Washington, the fight to preserve Black cemeteries
-
US children's book author sentenced to life after poisoning husband
-
Emotional Vin Diesel leads 'Fast and Furious' tribute in Cannes
-
NAV Fund Services (Ireland) Ltd. Expands European Fund Servicing Offering to Support UCITS Funds
-
AVI Urges the Dismissal of Two Directors at Wacom
-
PLAS-LABS Simplifies Scientific Validation With Automated Citation Tracking Powered by Bioz
-
Battery X Metals Achieves Milestone with Delivery of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Machine Featuring Design Enhancements, Advancing Strategic Commercialization Initiatives
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 14
-
Akkodis Recognized in HFS Horizons 2026 Report for Enterprise Ready Agentic AI Services
-
Lexus Of Oakville Recognized for Redefining the Luxury Dealership Experience With 2026 Consumer Choice Award
-
US renews offer of $100 mn to Cuba if it cooperates
-
City still 'alive' but need Arsenal slip: Guardiola
-
Man City ease past Palace to keep pressure on Arsenal
-
Alaves end champions Barca's bid for 100-point record
-
US jury begins deliberations on 737 MAX victim suit against Boeing
US House votes for life-changing $35 insulin price cap
US lawmakers voted Thursday on a bill limiting the cost of insulin to $35 a month, a transformative curb for millions of diabetics who pay hundreds of dollars for the life-sustaining hormone.
Drug pricing has vexed politicians for years in the United States, which has the highest annual health expenditure of any industrialized country, at around $11,000 per capita.
Insulin costs the 7.4 million American adults who use it to manage their diabetes eight times as much as in other wealthy nations, according to a 2020 study commissioned by the Health and Human Services Department.
"This is a kitchen table issue: are people going to be able to pay their bills? And it is, for us, a step in the direction of the (government) being able to negotiate for lower drug prices beyond insulin," House Speaker Nancy Pelosi told reporters.
The legislation passed the House of Representatives by 232 votes to 193, with a handful of Republicans crossing the aisle to join the Democrats, and now advances to the upper chamber of Congress, the US Senate.
It would require private health insurance companies to set prices for a month's supply of insulin at no more than $35, or 25 percent of a plan's negotiated price, whichever is lower, starting in 2023 for some patients and 2024 for all.
The cap was a provision in President Joe Biden's "Build Back Better" social welfare bill that was torpedoed by Democratic infighting in Congress late last year.
Biden brought the issue back into the spotlight during his State of the Union address on March 1, reinvigorating calls for action on pricing from diabetes advocates.
The effort is being seen as the only way for Democrats to show they're capable of acting on sky-high prescription drug prices before November's midterm elections.
- 'Costing a lot' -
The Senate is holding its own cross-party negotiations on driving down insulin costs by targeting the middlemen between health insurance companies and pharmacies.
And a separate Democrat-only bill from Georgia's Senator Raphael Warnock that would also cap the price at $35 is likely to be combined with the effort.
"I'm a pastor -- I'm on the ground -- and so I know that everybody knows somebody with diabetes," Warnock said in a video promoting his initiative.
Senate Majority Leader Chuck Schumer told reporters last week he believed a bipartisan bill had a good chance of passing when lawmakers return from a break at the end of April.
Research suggests that more than a quarter of Americans with type 1 diabetes have had to ration insulin they could not afford. Campaigners say the proportion went up to 50 percent during the pandemic.
It remains unclear if any legislation can gain the 10 Republican votes needed to advance in the Senate, but some opposition lawmakers have shown interest in an issue that affects voters across the board.
"I'd be for some kind of regulation where we can help. Too many people (are) paying thousands of dollars a month. I'm not big on regulating process, but that one's costing a lot of people a lot of money," Alabama Senator Tommy Tuberville told Axios.
Republicans on the powerful House Ways and Means Committee described the vote as "the largest expansion of federal command and control in Americans' private health insurance design" since the Affordable Care Act, the landmark 2010 regulatory overhaul and expansion of health care coverage.
"Democrats are reviving their socialist drug pricing scheme from their failed radical tax and spending spree," the committee's top Republican Kevin Brady said in a statement.
A.Moore--AT